MicroRNAs (miRNA) are small-noncoding RNAs of 21 nucleotides (nt) that regulate the expression of several genes.^[@bib1],\ [@bib2]^ Transcribed as-primary miRNAs are processed in the nucleus into 70--80 nt, hairpin-shaped precursors, called pre-miRNAs.^[@bib1],\ [@bib2]^ They are then exported in the cytoplasm and further processed into mature miRNAs (21 nt), and incorporated in the RNA-induced silencing complex.^[@bib1],\ [@bib2]^

The miR-125b is upregulated in many neoplastic blood disorders, including acute myeloid leukemia (AML).^[@bib3],\ [@bib4],\ [@bib5],\ [@bib6]^ Enforced constitutive overexpression of miR-125b in mice induces myeloid leukemia.^[@bib7]^ It has been indicated that miR-125b in a myeloid context, might act as an oncomiR able to transform cells by targeting multiple genes involved in apoptosis, cell cycle and differentiation (Tili *et al.*^[@bib6]^ and references therein). Relevant to myeloid leukemia, C/EBPα is frequently mutated in AML, but surprisingly, none of the observed mutations result in full ablation of the gene.^[@bib8],\ [@bib9]^ This indicates that activity of C/EBPα is required for AMLs, thus in addition to work as a tumor suppressor C/EBPα appears to be required for the development of at least some AML subtypes.^[@bib8],\ [@bib9],\ [@bib10]^ We previously showed that the manifestation of Hailey--Hailey disease, a rare skin disorder, was in part dependent on Notch1 downmodulation mediated by miR-125b upregulation.^[@bib11],\ [@bib12]^ Notably, although the involvement of Notch signaling as an oncogene in T-cell acute lymphoblastic leukemia (T-ALL) is well characterized, Notch signaling acts as a tumor suppressor in myeloid malignancies. Moreover, although T-ALL cells express Notch1 receptor, its expression is silenced in AML (Lobry *et al.*^[@bib13]^ and references therein). It has been previously shown that miR-125b is overexpressed in AML; thus, we investigated whether miR-125b overexpression might account for the differential Notch1 expression between T-ALL and AML. We compared miR-125b expression pattern in both primary AML and T-ALL leukemia as well as in AML and T-ALL-derived cell lines ([Figures 1a--d](#fig1){ref-type="fig"}). Both the human primary and AML cell lines samples demonstrated significant upregulation of miR-125b expression. Conversely, both primary and T-ALL cell lines failed to show significant enrichment of this miRNA.

In order to investigate whether the deregulation of miR-125b expression occurs either at the transcriptional or processing level, primary miR-125b expression levels were analyzed in both Jurkat and HL-60 cell lines, as well as in primary AML samples ([Figure 1e](#fig1){ref-type="fig"}, [Supplementary Figure S1](#sup1){ref-type="supplementary-material"}, [Supplementary Table 1](#sup1){ref-type="supplementary-material"} and [Supplementary Figure S7](#sup1){ref-type="supplementary-material"}). Specifically, quantitative reverse transcriptase PCR was performed to compare the levels of primary and mature miRNA. The primary miRNA levels of the miR-125b were found to parallel mature miR-125b expression in both cell lines examined ([Figures 1b and e](#fig1){ref-type="fig"}). In most primary AMLs, we found that miR-125b expression was transcriptionally upregulated ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). Nevertheless, we observe that in some samples primary miRNAs basal transcription efficiency was associated with a low abundance of the mature miRNA ([Figure 1a](#fig1){ref-type="fig"}, AMLs 8, 9 and 10). Thus, these observations indicated that in this cellular context there is generally a high rate of primary miR-125b transcription, although an altered processing efficiency might determine the level of mature miRNAs.

We found an inverse correlation of miR-125b expression and Notch1 protein levels in both T-ALL and AML cell lines, as well as in primary AML samples ([Figures 1b, d and f](#fig1){ref-type="fig"} and [Supplementary Figure S2](#sup1){ref-type="supplementary-material"}). We observed higher level of miR-125b expression in AML when compared with T-ALL samples ([Supplementary Figure S3](#sup1){ref-type="supplementary-material"}). Importantly, the Notch1 target genes, *Hes-1* and *Deltex1*, were significantly higher in T-ALL when compared with AML ([Supplementary Figure S3](#sup1){ref-type="supplementary-material"}). Recently, we found that *NOTCH1* is a target of miR-125b;^[@bib12]^ thus, we analyzed the potential involvement of miR-125b in regulating the differential expression of Notch1 between T-ALL and AML cells. We analyzed Notch1 protein expression after overexpression of either miR-125b or AntagomiR-125b in T-ALL and AML cell lines, respectively.

DND41 cells, but not Jurkat and HL-60 cells, are highly transfectable. To overcome these limitations, DND41 cells were analyzed by transient transfection and both Jurkat and HL-60 cells were transduced by lentiviral infection. We found that deregulated miR-125b expression impaired Notch1 levels in DND41 ([Figure 1g](#fig1){ref-type="fig"}), and although with a lower effect also in Jurkat and HL-60 cell lines ([Figure 1h](#fig1){ref-type="fig"}). Together, these results suggest that deregulation of miR-125b expression has a critical role in the differential expression of Notch1 between T-ALL and AML. However, ME-1 cells devoid of miR-125b expression have undetectable level of Notch1 expression ([Figures 1b and f](#fig1){ref-type="fig"}). Additionally, in the T-ALL derived cell line, Molt3, miR-125b enforced expression did not affect Notch1 expression (data not shown); thus, it is likely that other mechanisms alone or synergistically with the miR-125b are involved in Notch1 downmodulation in AML^[@bib14]^ or alternatively an unknown mechanism antagonizes the repressive activity of miR-125b on the 3′-untranslated region of *Notch1* in a cell context-specific manner.

To explore the mechanism regulating miR-125b expression, we first characterized the miR-125b promoter region using the Genomatix MatInspector software package (Genomatix Software GmbH, Munich, Germany), focusing on those transcription factors that have been shown to have a role in either T-ALL or AML. A scan of 2 kb of genomic sequence located upstream of the predicted pre-miR-125b start site identified putative Hes-1, GATA3 and one C/EBPα consensus binding sites ([Figure 2a](#fig2){ref-type="fig"}), suggesting the involvement of those factors in the regulation of miR-125b expression. Thus, protein extracts from AML and T-ALL-derived cell lines were first analyzed for expression of those factors. Interestingly, C/EBPα expression was correlated with miR-125b expression in the cell lines examined ([Figures 1b--d and 2b](#fig1){ref-type="fig"}). We next examined the role of these transcription factors in the regulation of miR-125b expression by generating a miR-125b promoter construct and testing it in a luciferase reporter assay. As shown in the [Figure 2c](#fig2){ref-type="fig"}, we found the induction of miR-125b promoter activity by C/EBPα transfection in a dose-dependent fashion, but neither by HES-1 nor GATA3 (data not shown), indicating that C/EBPα might be a transcriptional regulator of miR-125b expression. C/EBPα is a key myeloid transcription factor, frequently mutated in AML, but none of the described mutations result in the full loss of its function.^[@bib10]^ Recently, it has been shown that C/EBPα-dependent activity has an important role in AML etiology.^[@bib10]^ Next, we investigated whether C/EBPα directly regulates miR-125b promoter. To test whether C/EBPα binds directly to the miR-125b promoter, we performed chromatin immunoprecipitation experiments in both HL-60 cells and primary AML samples. The chromatin fragments were immunoprecipitated with an anti-C/EBPα antibody. The DNA fragments were analyzed with specific primers for the indicated regions of the miR-125b regulatory region ([Figure 2d](#fig2){ref-type="fig"} and [Supplementary Figure S4](#sup1){ref-type="supplementary-material"}). We were able to observe an enrichment of DNA from the predicted C/EBPα-binding sites when compared with the immunoglobulinG control ([Figure 2d](#fig2){ref-type="fig"}). Additionally, we observed an increased recruitment of C/EBPα onto the miR-125b promoter in AML primary samples highly expressing miR-125b primary transcript ([Supplementary Figures S1](#sup1){ref-type="supplementary-material"} and [S4](#sup1){ref-type="supplementary-material"}).

The myeloid cell lines provide an important *in vitro* model system for studying the cellular and molecular events involved in the proliferation and differentiation of normal and leukemic cells of the granulocyte/monocyte/macrophage lineage. Both HL-60 and NB4 pro-myelocytic leukemia cell lines have the potential to differentiate toward granulocytic lineage by exposure to retinoic acid. Thus, to explore further the role of C/EBPα in the induction of miR-125b expression, we compared C/EBPα and miR-125b expression after retinoic acid treatment ([Figure 2e](#fig2){ref-type="fig"}). Treatment with retinoic acid (1 μ[m]{.smallcaps}) strongly decreased both C/EBPα protein and mRNA expression ([Figure 2e](#fig2){ref-type="fig"} and [Supplementary Figure S5a](#sup1){ref-type="supplementary-material"}), in parallel with induction of granulocytic differentiation ([Supplementary Figure S5](#sup1){ref-type="supplementary-material"}). Notably, in both cell lines, HL-60 and NB4, the downregulation of C/EBPα expression by retinoic acid parallels that of miR-125b ([Figure 2e](#fig2){ref-type="fig"} and [Supplementary Figure S6](#sup1){ref-type="supplementary-material"}). Interestingly a similar parallel expression was observed in CD34+ and CD34− primary cells ([Figure 2f](#fig2){ref-type="fig"}). Finally, small interfering RNA against C/EBPα in HL-60 abolished the basal level of miR-125b expression ([Figure 2g](#fig2){ref-type="fig"}), further supporting our finding that miR-125b is a direct target of C/EBPα.

In summary, several studies have made important advances in elucidating the contribution of both C/EBPα and miR-125b into the molecular mechanisms of AML development. Our study implicates the transcription factor C/EBPα as a critical determinant of miR-125b expression in AML, supporting a model whereby C/EBPα functions to enhance miR-125b expression to regulate a group of genes whose deregulation leads to acute myeloid transformation.
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![miR-125b is upregulated in AML patient samples. (**a**) qRT-PCR for miR-125 was carried out using bone marrow cells derived from AML patient samples (*n*=10 and healthy donors CD34− cells). Values were normalized to U6 and further to the expression level of three healthy donors. (**b**) qRT-PCR for miR-125b was carried out using AML-derived cell lines, values are expressed as fold increase over Jurkat cells. Values were normalized to U6. (**c**) qRT-PCR for miR-125 was carried out using PBC cells derived from T-ALL patient samples (*n*=7 and healthy donors CD4+ cells). Values were normalized to U6 and further to the expression level of three healthy donors. (**d**) qRT-PCR for miR-125b was carried out using T-ALL-derived cell lines, values are expressed as fold increase over CD4+ healthy donor-derived cells. Values were normalized to U6. (**e**) pri-miR-125b-1 and two transcripts were determined by qRT-PCR in the indicated cells. (**f**) Western blot analysis of Notch1 expression in whole cell extract in the indicated cell lines. Tubulin is shown as a loading control. (**g**) DND41 cell line were transfected with either miR-ctr or mature miR-125b, and mature miR-125b expression was analyzed by qRT-PCR (left). miR-ctr and miR-125b transfected cells were analyzed by western blot with the indicated antibodies. (**h**) Left panel, T-ALL- (Jurkat) and AML (HL-60)-derived cell lines were infected with either miR-ctr/miR-125b or MiRZIP-ctr/MiRZIP125b, and Notch1 mRNA expression was analyzed. Right panel, miR-125b expression was evaluated in the samples shown in the left panel. All results were expressed as means±s.d., and *P*-values are indicated.](leu2015117f1){#fig1}

![miR-125b is a direct target of C/EBPα. (**a**) Schematic representation of examined putative C/EBPα-binding sites in the promoter regions of miR-125b. (**b**) C/EBPα protein expression assessed by western blotting in the indicated cell lines. (**c**) HEK293T cells were transfected with miR-125b-luciferase responsive promoter construct, 0.25 μg/well in 24-well dishes, and treated with the indicated amount of C/EBPα cells were harvested 24 h after transfection for luciferase assay. All conditions were tested in triplicate samples and s.d. is indicated. (**d**) Chromatin derived from HL-60-C/EBPα-positive cells was immunoprecipitated with anti- C/EBPα or IgG antibodies. Recovered DNA was PCR amplified with primers specific for C/EBPα-binding amplificon. Shown is the fold change in binding affinity of the anti-C/EBPα antibody normalized to IgG. Immunoprecipitation was performed three times using different chromatin samples, and the occupancy was calculated by using the ChIP-qPCR Human IGX1A Negative Control Assay (Qiagen, Milano, Italy) as a negative control. As additional control recovered DNA was PCR amplified with primers specific for Hes-1-binding amplificon in the eIF6 promoter lacking of C/EBPα-binding site.^[@bib15]^ (**e**) miR-125b and C/EBPα mRNA expression was analyzed at 0, 12, 24 and 48 h post RA treatment of HL-60 cells. (**f**) miR-125b and C/EBPα mRNA expression in CD34+ versus CD34− human primary cells. (**g**) miR-125b expression of C/EBPα-silenced HL-60 cells, as assessed by qRT-PCR. (**h**) A scheme showing transcriptional regulation and function of miR-125b in AML. miR-125b is induced by both WT and mutant C/EBPα. High expression of miR-125b leads to differentiation block, proliferation and transformation. In parallel miR-125b decreases Notch1 protein level, which has also been implicated in suppression of AML cell growth.](leu2015117f2){#fig2}

[^1]: Dedicated to the cherished memory of Alberto Gulino.
